Elsevier

Metabolism

Volume 41, Issue 9, Supplement 2, September 1992, Pages 104-110
Metabolism

In vitro detection of somatostatin receptors in human tumors

https://doi.org/10.1016/0026-0495(92)90042-9Get rights and content

Abstract

Somatostatin receptors (SSR) have been identified in membrane homogenates or tissue sections from several hundred human tumors. SSR have been found in most neuroendocrine tumors, ie, growth hormone (GH)- and thyrotropin (TSH)-producing pituitary tumors, endocrine gastroenteropancreatic (GEP) tumors, paragangliomas, pheochromocytomas, medullary thyroid carcinomas (MTC), and small-cell lung carcinomas. SSR have also been found in the majority of malignant lymphomas, in several brain tumors (all meningiomas, most astrocytomas), and in breast tumors. The majority of tumors expressing SSR are rather differentiated, eg, astrocytomas in contrast to glioblastomas, but exceptions such as high-grade malignant lymphomas do exist. An inverse relationship exists between SSR and receptors for epidermal growth factor in lung tumors, glial tumors, and most breast tumors, whereas meningiomas express both receptors simulataneously. A minority of tumors such as ovarian tumors, MTC, and insulinomas express a subtype of SSR characterized by low affinity for the octapeptide SS analogue, octreotide. The function of SSR in human tumors differs according to tumor type; SSR in pituitary and GEP tumors mediate hormone secretion inhibition and possibly have some antiproliferative effects. However, in meningiomas, activation of SSR inhibits forskolin-stimulated adenylate cyclase activity and weakly stimulates proliferation. Although SSR seem to mediate antiproliferative effects in animal models and cell lines of lymphomas and breast and lung tumors, such an effect has not yet been convincingly documented in human primary tumors. The clinical implications of the presence of SSR in tumors are as follows: as a predictive marker for efficient therapy with octreotide in pituitary and GEP tumors; as a diagnostic marker for pathobiochemical classification of tumors using in vitro detection methods; as a diagnostic marker for clinical evaluation using in vivo scanning techniques; as a prognostic marker; and as a potential target for radiotherapy.

References (32)

  • JC Reubi et al.

    In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas

    Int J Cancer

    (1992)
  • JC Reubi et al.

    Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF receptors

    Int J Cancer

    (1990)
  • M Papotti et al.

    Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas

    Int J Cancer

    (1989)
  • JC Reubi et al.

    Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas

    Cancer Res

    (1990)
  • JC Reubi et al.

    Somatostatin receptors and somatostatin content in medullary thyroid carcinomas

    Lab Invest

    (1991)
  • JC Reubi et al.

    Somatostatin receptors are present in small cell but not in non-small cell primary lung carcinomas: Relationship to EGF-receptors

    Int J Cancer

    (1990)
  • Cited by (0)

    This paper (with virtually the same content) will also publish in a supplement to Digestive Diseases and Sciences (in press).

    View full text